^
    Back
    Association details:
    Biomarker:BRAF V600E
    Cancer:Cutaneous Melanoma
    Drug:Zelboraf (vemurafenib) (BRAF inhibitor, BRAF V600E inhibitor) +
    Cotellic (cobimetinib) (MEK1 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A2 - Guideline
    Source:
    NCCN
    Published date:
    02/19/2021
    Excerpt:
    Melanoma: Cutaneous...BRAF/MEK Combinations…Vemurafenib/cobimetinib…Unresectable or metastatic melanoma with BRAF V600E mutation as detected by an FDA-approved test
    Test:
    FoundationOne® CDx, cobas® 4800 BRAF V600 Mutation Test
    Evidence Level:
    Sensitive: C1 - Off-label
      (Approved for Melanoma)
    New
    Excerpt:
    COTELLIC is a kinase inhibitor indicated for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, in combination with vemurafenib.